These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3087473)

  • 21. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Raynaud's phenomenon and scleroderma].
    LANGERON L; CROCCEL L; LANGERON P
    J Sci Med Lille; 1959; 77():380-5. PubMed ID: 14413955
    [No Abstract]   [Full Text] [Related]  

  • 23. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon.
    Pancera P; Sansone S; Presciuttini B; Montagna L; Cerù S; Lunardi C; Lechi A
    Clin Sci (Lond); 1999 Jan; 96(1):49-57. PubMed ID: 9857106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scleroderma and Raynaud's phenomenon.
    BARNETT AJ
    Clin Rep; 1959; 9():33-74. PubMed ID: 13796900
    [No Abstract]   [Full Text] [Related]  

  • 26. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma.
    Maricq HR
    Arch Dermatol; 1992 May; 128(5):630-2. PubMed ID: 1575525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis.
    von Schoen-Angerer T; Deckers B; Henes J; Helmert E; Vagedes J
    Complement Ther Med; 2018 Oct; 40():191-194. PubMed ID: 30219447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raising awareness of Raynaud's phenomenon and scleroderma.
    Mawdsley AH; Brown SJ
    Nurs Times; 2005 Feb 22-28; 101(8):30-1. PubMed ID: 15754937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Raynaud's syndrome and scleroderma. I. Scleroderma-like changes in Raynaud's syndrome and their differentiation from scleroderma].
    JABLONSKA S; LUKASIAK B; BUBNOW B
    Pol Tyg Lek (Wars); 1957 Sep; 12(39):1481-6. PubMed ID: 13505250
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's phenomenon in limited cutaneous systemic sclerosis.
    Bonnecaze AK
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26715139
    [No Abstract]   [Full Text] [Related]  

  • 33. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [SCLERODERMA COEXISTING WITH RAYNAUD'S PHENOMENON].
    JABLONSKA S; SZCZEPANSKI A
    Przegl Dermatol; 1964; 51():129-36. PubMed ID: 14231463
    [No Abstract]   [Full Text] [Related]  

  • 37. Lymphocyte-endothelium interaction in systemic sclerosis and Raynaud's phenomenon.
    Della Bella S; Molteni M; Mocellin C; Fumagalli S; Bonara P; Scorza R
    Clin Exp Rheumatol; 2001; 19(6):647-54. PubMed ID: 11791635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.
    Delisle VC; Hudson M; Baron M; Thombs BD; And The Canadian Scleroderma Research Group A
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-10-4. PubMed ID: 24144459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
    Ramos-Casals M; Brito-Zerón P; Nardi N; Claver G; Risco G; Parraga FD; Fernandez S; Julià M; Font J
    Rheumatology (Oxford); 2004 Nov; 43(11):1454-6. PubMed ID: 15502001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.